About Life Sciences Pittsburgh
Life Sciences Pittsburgh is an initiative led by the Pittsburgh Innovation District in collaboration with the University of Pittsburgh, Bio Breakfast, Innovation Works, Life Sciences Pennsylvania, Magee-Womens Research Institute, Pittsburgh Life Sciences Greenhouse, UPMC Enterprises, and Women in Bio Pittsburgh. The site was launched to enhance the region’s connectivity around life sciences and attract new investments and industry partners.
Accelerating Pittsburgh’s life sciences industry and growing the region’s life sciences ecosystem will amplify Pittsburgh’s leading position in healthcare and research.
Rebecca Bagley serves as Vice Chancellor for Economic Partnerships and works with senior leadership at Pitt to develop a strategic plan for the University in economic development. She is also developing and overseeing effective public and private partnerships that connect and advance the University and have regional and national impact. She serves as a liaison with government, community leadership and the business community on matters pertaining to economic development.
Michael Annichine is the CEO of Magee-Womens Research Institute and Foundation (MWRIF), the largest research institute in the world focused exclusively on the health of women and infants, and home to world class researchers who have devoted their careers to women’s health and reproductive biology. Under Michael’s leadership MWRIF plans to expand its revenue base and capitalize on the significant translational impact of its scientific investment. Michael is a seasoned professional with more than 20 years’ experience starting, developing and leading local and national businesses across a variety of growth industries. A Carnegie Mellon Alumni and former Director of Investment Programs at the Pittsburgh Life Sciences Greenhouse, he has had significant impact on the Pittsburgh start-up community, and built strong connections and a reputation of success within the business, private equity, and venture capital communities.
C. Talbot Heppenstall, Jr., has been treasurer at UPMC since 2003 and executive vice president since 2013. Mr. Heppenstall is responsible for overseeing the day-to-day cash needs of UPMC, along with the investment management of its $5 billion of cash and investments, its pension portfolio and oversight of its outstanding municipal bonds and other debt. As president of UPMC Enterprises, Mr. Heppenstall is leading UPMC’s efforts to commercialize its managerial and health care expertise, particularly in the area of information technology. With a focus first on improving the quality, efficiency and patient experience at UPMC, the division and its partners will then take those solutions to the broader health care market. He earned a bachelor’s degree from the University of Virginia and a master’s degree from Carnegie Mellon University.
Jim Jordan is an accomplished Fortune 20-level executive with strong experience in industry, consulting and academia. A recognized expert in translational innovation, market development and guiding the successful formation of entrepreneurial startup businesses in the Life Sciences Industry, Mr. Jordan joined the PLSG in 2005. Prior to joining the PLSG, Mr. Jordan served as Senior Vice President of a $3.0 billion division of McKesson Corporation, and as a Vice President for Marketing at Johnson & Johnson. Mr. Jordan joined Carnegie Mellon University’s Heinz College in 2005 and serves as the Sr. Director and Distinguished Service Professor of Health Care and Biotechnology Programs, and also as Strategic Board Chairman-Center for Healthcare Innovation.
As President & CEO of Innovation Works, one of the nation’s most active early-stage investors, Rich Lunak leads the organization’s efforts to provide business expertise, seed capital and other resources to high-potential, technology start-up companies in Pittsburgh.
Prior to joining Innovation Works, Rich was a successful technology entrepreneur/inventor who built one of Pittsburgh’s most successful and enduring technology start-ups. He helped lead a healthcare robotics company from a three-person start-up to an acquisition by McKesson Corporation. He is a guest lecturer at the University of Pittsburgh and Carnegie Mellon and is a member of numerous Boards of Directors. He is a winner of the 2012 Ernst and Young Entrepreneur of the Year Award and the 2008 Carnegie Science Center entrepreneur’s award.
Evan is the Interim Director of the Innovation Institute. Before joining Pitt, Evan was President/CEO of SironRX Therapeutics, a biotechnology company developing novel drug therapies. Prior to this, Evan worked in Bayer Healthcare’s medical device division as General Manager of Pittsburgh Interventional. While here he also served as Executive Director, Corporate Development overseeing company strategy and M&A. Before this, Evan was Senior Manager, Business Development at the biotechnology company Athersys where he was a leader in creating partnerships with global pharmaceutical companies such as Pfizer, Bristol-Myers Squibb and Johnson & Johnson among others. Evan holds a Ph.D. in Human Genetics from the University of Pittsburgh, an MBA with a concentration in Entrepreneurship from Case Western Reserve University and a B.S. in Biology from the University of Miami.
Christian Manders is the Chief Operating Officer for Promethean LifeSciences. He is responsible for overseeing the daily operations of the company. He has successfully gained FDA approval for their products, GammaGraft and Repriza, human skin allograft products for the treatment of wounds and reconstructive procedures. He has served on the Board of Governors of the American Association of Tissue Banks, serves on the Board of Life Sciences Pennsylvania (www.lifesciencespa.org), the second biggest state-wide industry group for the life sciences in the United States, founded and runs the Pittsburgh Biomedical Breakfasts (www.biobreakfast.com), and is active in the life sciences community in Pittsburgh.
Donald P. Taylor, PhD, MBA, is assistant vice chancellor for commercial translation in the health sciences; of Medicine; and visiting associate professor of bioengineering, Swanson School of Engineering. His responsibilities include working across the six health sciences schools to accelerate commercial translation of Pitt’s discoveries and inventions, grow academic and industry partnerships, secure commercial translation grant opportunities, and help train the next generation of world-class translational development students, staff, and faculty. A longtime life sciences entrepreneur, Dr. Taylor previously served as CEO of healthStratica LLC and as an executive-in-residence at the Pittsburgh Life Sciences Greenhouse. He was vice president of corporate development for Cellumen Inc., a bio-tools company, and for its predecessor company, Cernostics Inc., a cancer molecular diagnostics company.
Christopher P. Molineaux serves as the President and Chief Executive Officer of Life Sciences Pennsylvania, overseeing the strategic direction for the association, assuring that LSPA continues to be the catalyst that makes Pennsylvania the top location for life sciences companies. Mr. Molineaux has over 25 years of experience in the bio-pharmaceutical and health care industries, with front-line experience in developing and executing strategies to navigate a shifting economic and political environment. He joined Pennsylvania Bio in 2009 as senior vice president for membership services, responsible for managing and enhancing the relationship between the association and member companies, and for developing and executing the strategic membership plan for the association’s continued growth.